

Viewpoint: Implementation of a liver health check in people with type 2 diabetes

Authors: Kushala WM Abeysekera^{1,2}, Luca Valenti^{3,4}, Zobair Younossi⁵, John F Dillon⁶, Alina M. Allen⁷, Mazen Nourredin⁸, Mary E. Rinella⁹, Frank Tacke¹⁰, Sven Francque^{11,12}, Pere Gines^{13,14,15,16}, Maja Thiele¹⁷, Philip N Newsome¹⁸, Indra Neil Guha¹⁹, Mohammed Eslam²⁰, Jörn M. Schattenberg²¹, Saleh A. Alqahtani^{22,23}, Marco Arrese²⁴, Annalisa Berzigotti²⁵, Adriaan G. Holleboom²⁶, Cyrielle Caussy^{27,28}, Kenneth Cusi²⁹, Michael Roden^{30,31,32}, Hannes Hagström³³, Vincent Wai-Sun Wong³⁴, Vincent Mallet^{35,36}, Laurent Castera³⁷, Jeffrey V. Lazarus^{38,39}, Emmanuel A. Tsochatzis^{40,41}

Affiliations:

1. Population Health Sciences, Bristol Medical School, University of Bristol, UK
2. Department of Liver Medicine, Bristol Royal Infirmary, Bristol, UK.
3. Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
4. Precision Medicine, Biological Resource Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy
5. Beatty-Liver and Obesity Research Program, Department of Medicine at Inova Fairfax Medical Campus, Inova Medicine, Falls Church, Virginia, USA
6. Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK
7. Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
ORCID [0000-0002-8393-8410](https://orcid.org/0000-0002-8393-8410)
8. Houston Methodist Hospital, Houston Research Institute, Houston, Texas
9. The University of Chicago Pritzker School of Medicine, Chicago, IL
10. Department of Hepatology & Gastroenterology, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany;
frank.tacke@charite.de
11. Department of Gastroenterology Hepatology, Antwerp University Hospital, Edegem, Belgium

12. Translational Sciences in Inflammation and Immunology, Laboratory of experimental medicine and paediatrics, Faculty of Medicine and Health Care Sciences, University of Antwerp, Wilrijk, Belgium; svn.francque@uza.be; ORCID: 0000-0002-7527-4714
13. Liver Unit, Hospital Clínic, Barcelona, Catalonia, Spain
14. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
15. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEReHD), Spain
16. Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Catalonia, Spain
17. Center for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, and Department for Clinical Research, University of Southern Denmark, Odense, Denmark. Maja.thiele@rsyd.dk ORCID 0000-0003-1854-1924
18. National Institute for Health Research, Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Centre for Liver & Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
19. NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
20. Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, NSW, Australia.
21. Metabolic Liver Research Program, I. Department of Medicine, University Medical Center Mainz; ORCID: 0000-0002-4224-4703
22. Liver Transplant Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
23. Division of Gastroenterology & Hepatology, Johns Hopkins University, Baltimore, MD, USA
24. Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. marrese@uc.cl; ORCID: 0000-0002-0499-4191

25. Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Switzerland annalisa.berzigotti@insel.ch ORCID 0000-0003-4562-9016
26. Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef, Amsterdam, the Netherlands
27. University of Lyon, CarMen Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69495 Pierre-Bénite, France
28. Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, 69495 Pierre-Bénite, France ORCID 0000-0001-8089-2907
29. Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida
30. Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
michael.roden@ddz.de; ORCID 0000-0001-8200-6382
31. Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
32. German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany
33. Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
34. Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
35. Université Paris Cité, F-75006, Paris, France
36. AP-HP.Centre, Groupe Hospitalier Cochin Port Royal, DMU Cancérologie et Spécialités Médico-Chirurgicales, Service d'Hépatologie, Paris, France
37. Department of Hepatology, Beaujon Hospital, Université Paris Cité, INSERM UMR1149, Clichy, France
38. CUNY Graduate School of Public Health and Health Policy, NY, NY, USA

39. Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain, ORCID: 0000-0001-9618-2299

40. Sheila Sherlock Liver Unit, Royal Free Hospital, London, UK

41. UCL Institute of Liver and Digestive Health, University College London, UK

Author correspondence:

Professor Emmanuel A. Tsochatzis

UCL Institute for Liver and Digestive Health

Royal Free Hospital and UCL

Pond Street, NW3 2QG

London, UK

Email: e.tsochatzis@ucl.ac.uk

Keywords: alcohol-related liver disease, cirrhosis, elastography, ELF, fibrosis, FIB-4, hepatocellular carcinoma, NAFLD, obesity.

Conflicts of interest:

KWMA: Nothing to disclose

LV: consulting fees from Gilead, Pfizer, Astra Zeneca, Novo Nordisk, Intercept pharmaceuticals, Diatech Pharmacogenetics, IONIS, Boehringer Ingelheim, grant support from Gilead, Speaker fees from MSD, Gilead, AlfaSigma, AbbVie, Viatrix.

ZY: Nothing to disclose

JFD: consulting fees from Intelligent Ultrasound, speaker fees for Gilead and GE systems.

AMA: Consulting fees from NovoNordisk, grant support from Target, NovoNordisk and Pfizer.

MN: consulting fee from Altimune, BI, Cytodyn, 89BIO, GSK, Madrigal, Merck, Novo Nordisk, Northsea therapeutics, Prespecturm, Terns and Takeda, grant support from Allergan, Akero, BMS, Gilead, Galectin, Genfit, GSK, Conatus, Corcept, Enanta, Madrigal, Novartis, Novo Nordisk, Shire, Takeda, Terns, Viking and Zydus, stock options from Rivus Pharma, CIMA, Cytodyn, and ChronWell

MER: consulting fees from Intercept Pharmaceuticals, Gilead Sciences, Genfit, NGM Biopharmaceuticals, Enanta, Immuron, Fractyl, Prociento, Gelesis, Merck, Bristol-Myers Squibb, Metacrine, Viking Therapeutics, Allergan, Cymabay, Boehringer Ingelheim,

Genentech, 89Bio, Galecto, Terns, Sagimet, Thetis, Fractyl, Lipicine, GSK, Coherus and Novartis.

FT: consulting fees for Allergan, AstraZeneca, Bayer, Gilead, BMS, Boehringer, Intercept, Ionis, Inventiva, Merz, Pfizer, Alnylam, NGM, CSL Behring, Madrigal, Novo Nordisk, Novartis, grant support from Allergan, BMS, Inventiva, Gilead (funding to institution), speaker fees from Gilead, AbbVie, Falk, Merz, Intercept, Sanofi, Astra Zeneca, expert testimony for Alnylam, data safety monitoring board for Pfizer and travel support from Gilead.

SF: Consulting fees from Abbvie, Actelion, Aelin Therapeutics, Aligos Therapeutics, Allergan, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Meyers Squibb, CSL Behring, Coherus, Echosens, Eisai, Enyo, Galapagos, Galmed, Genetech, Genfit, Gilead Sciences, Intercept, Inventiva, Janssens Pharmaceutica, Julius Clinical, Madrigal, Medimmune, Merck Sharp & Dome, NGM Bio, Novartis, Novo Nordisk, Promethera, Roche, research grants from Astellas, Falk Pharma, Genfit, Gilead Sciences, GlympsBio, Janssens Pharmaceutica, Inventiva, Merck Sharp & Dome, Pfizer, Roche and speaker fees from Abbvie, Allergan, Bayer, Eisai, Genfit, Gilead Sciences, Janssens Cilag, Intercept, Inventiva, Merck Sharp & Dome, Novo Nordisk, Promethera

PG: Nothing to disclose

MT: Speaker fees from Echosens and Siemens Healthcare.

PNN: consulting fees from B Ingelheim, Intercept, Madrigal, BMS, Astra Zeneca, Gilead, Pfizer, GSK, Novo Nordisk, Poxel Pharmaceuticals, Sun Pharma and grant support from NovoNordisk.

ING: Grant support from Gilead

ME: Nothing to disclose

JS: consulting fees from Apollo Endosurgery, Albireo Pharma Inc, Bayer, Boehringer Ingelheim, Gilead Sciences, GSK, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Madrigal, MSD, Northsea Therapeutics, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Siemens Healthineers, grant support from Gilead Sciences, Boehringer Ingelheim, Siemens Healthcare GmbH and speaker fees from Boehringer Ingelheim, Echosens, MedPublico GmbH, Novo Nordisk, Madrigal Pharmaceuticals.

SAA: Nothing to disclose

MA: Nothing to disclose

AB: Consulting fees from Inventiva, grant support from Boehringer-Ingelheim

AGH: Consulting fees from Inventiva, Echosens, Novo Nordisk, Gilead, Julius Clinical

CC: Consulting fees from NovoNordisk, Gilead, AstraZeneca, Bayer, E-Scopics, Intercept, Lilly, research support from Echosens, E-scopics and Gilead and speaker fees from Madrigal, AstraZeneca, Gilead, NovoNordisk, Lilly, LVL

KC: Consulting fees from Altimmune, Arrowhead, AstraZeneca, Boehringer Ingelheim, Covance, 89Bio, BMS, Lilly, Madrigal, Merck, Myovant, Novo Nordisk, Prosciento, Quest, Sagimet, Sonic Incytes, and Terns and grant support from Echosens, Inventiva, Novo Nordisk, Nordic Bioscience, Poxel, Labcorp, and Zydus.

MR: Consulting fees from Boehringer, Pfizer, NovoNordisk and Eli Lilly, grant support from Boehringer, NovoNordisk, Nutricia Danone, Sanofi.

HH: Consulting fees from Astra Zeneca, grant support from Astra Zeneca, EchoSens, Gilead, Intercept, MSD and Pfizer

VWSW: Consulting fees from AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions, Visirna, speaker fees from AbbVie, Gilead Sciences, Novo Nordisk, Unilab, travel support from AbbVie, Gilead Sciences, grant support from Gilead Sciences, stock options for Illuminatio Medical Technology Limited.

VM: Nothing to disclose

LC: Consulting fees from Echosens, Madrigal, MSD, Novo Nordisk, Pfizer, Sagimet, and Siemens healthineers and speaker fees from Echosens, Inventiva and Novo Nordisk.

JVL acknowledges grants and speaker fees from AbbVie, Gilead Sciences, MSD and Roche Diagnostics and speaker fees from Intercept, Janssen, Novo Nordisk and ViiV, outside of the submitted work.

EAT: consulting fees from Alexion, NovoNordisk, Pfizer, Boehringer, Orphalan, Univar and speaker fees from NovoNordisk, Orphalan and Dr Falk.

Contributions: Kush Abeysekera wrote the original draft. Luca Valenti, Zobair Younossi, John Dillon, Alina Allen, Mazen Nourredin, Mary Rinella, Frank Tacke, Sven Franque, Pere Gines, Maja Thiele, Phil Newsome, Neil Guha, Mohammed Eslam, Jorn Schattenberg, Saleh Alqahtani, Marco Arrese, Annalisa Berzigotti, Onno Holleboom, Cyrielle Caussy, Keneth Cusi, Michael Roden, Hannes Hagstrom, Vincent Wong, Vincent Mallet, Laurent Castera and Jeff Lazarus writing, reviewing and editing. Emmanuel A. Tsochatzis conceptualisation and writing - review and editing.

Search strategy and selection criteria

We searched Medline (January 1, 2005–January 15, 2023) using the search term “diabetes” combined with the terms “NAFLD”, “cirrhosis”, “ALD”, “FIB-4”, “ELF”, or “Fibroscan” without language restrictions. We selected further relevant publications from the reference lists of articles identified by this search strategy. We largely selected publications from the past 5 years, but did not exclude highly relevant older publications. Review articles are cited to provide more details and references than this Viewpoint has room for.

Abstract

As morbidity and mortality related to potentially preventable liver diseases is on the rise globally, early detection of liver fibrosis offers a window of opportunity to prevent disease progression. Early detection of non-alcoholic fatty liver disease (NAFLD) allows for initiation and reinforcement of weight management guidance, risk stratification for advanced liver fibrosis and treatment optimisation of diabetes and other metabolic complications. Identification of alcohol-related liver disease provides the opportunity to support patients with detoxification and abstinence programmes. In all patient groups, identification of cirrhosis ensures that patients are enrolled in hepatocellular carcinoma (HCC) and portal hypertension surveillance programmes.

When considering early detection strategies, success can be achieved from applying ad-hoc screening for liver fibrosis in established frameworks of care. Patients with type 2 diabetes (T2D) are an important group to consider case finding of (advanced) liver fibrosis and cirrhosis, as almost 70% have NAFLD and up to 19% have advanced fibrosis, which is 10-fold higher than the general population. Additionally, T2D patients with alcohol use disorders have the highest proportion of liver related morbidity. Patients with T2D receive an annual diabetes review as part of their routine clinical care, where the health of many organs are considered. Yet, liver health is seldom included in this review. This viewpoint argues that augmenting the existing risk stratification strategy with an additional “Liver Health Check” provides the opportunity to detect advanced liver fibrosis, thereby opening a window for early interventions to prevent end-stage liver disease and its complications, including HCC.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is prevalent in over 30% of the global adult population (1) and is the main reason for referral to hepatology services. NAFLD is a spectrum ranging from isolated steatosis (non-alcoholic fatty liver, NAFL) to steatohepatitis (NASH) with or without fibrosis, with some patients ultimately progressing to cirrhosis and/or hepatocellular carcinoma (HCC). A systematic review using the Global Burden of Disease study data between 1990-2017 showed that NAFLD was the only liver condition where age-standardised death rates increased, with annual cases of cirrhosis deaths almost doubling, from approximately 61,900 cases in 1990 to 118,000 cases in 2017 (2). Modelling from Canada suggests that NAFLD will overtake ARLD as the major cause of cirrhosis by 2040 (3).

Currently, an estimated 5% of the adult global population have NASH (1). These patients are at significant risk of developing advanced fibrosis, which has been repeatedly associated with liver related morbidity and mortality (4). In the UK and US, NASH cirrhosis is now the second commonest indication for liver transplantation, after ARLD, and the leading indication in women (5, 6). There are further implications for transplant services as steatotic donor grafts are associated with poorer outcomes (7).

HCC incidence in patients with NASH cirrhosis ranges between 1-3% annually, with the number of new cases predicted to increase by 55% by 2040 (8). Importantly, HCC risk in patients with seemingly benign NAFL and no fibrosis is ten times higher than in the general population (9). Crucially, patients with NAFLD-related HCC tend to be older and have greater cardiovascular comorbidity. They also often present at a later stage because most are not under a HCC screening programme, are less likely to fulfil criteria for curative liver transplantation and, ultimately, have worse survival outcomes (10).

Despite this landscape of rising NAFLD-related morbidity and mortality, and a recent consensus for an international NAFLD public health agenda (11), awareness amongst clinicians and policy preparedness remains low. In a global survey with responses from 102 countries, no country had a national strategy for NAFLD and only 32 countries had national NAFLD clinical guidelines (12). In a cross-sectional survey of public health responses across

29 European countries, ten had national NAFLD guidelines, of which all recommended screening for NAFLD in type 2 diabetes (T2D) (13).

The rise in NAFLD prevalence parallels that of T2D, obesity and cardiovascular disease, which are all associated with insulin resistance. In the context of this interlinked pathophysiology between NAFLD, insulin resistance and T2D, almost 70% of T2D patients will have some degree of NAFLD, with an estimated 58% having NASH and up to 38% having advanced fibrosis (14, 15). The rate of hospitalization and death (not including HCC) due to liver disease in patients with T2D is 25.9 and 7 per 10,000 patients/years respectively and it is 2-3 times higher than the non-diabetic population (16, 17). Vice versa, lipotoxicity in NAFLD induces hepatic insulin resistance, generating uncontrolled gluconeogenesis and contributing to T2D (18). Indeed, patients with NAFLD have a two-fold higher incidence rate of T2D (19). This reflects the bidirectional relationship between these diseases.

It is worth acknowledging that not only NAFLD, but also ARLD co-exists with T2D. Mallet et al presented an 11-year French cohort study of 52,066 patients with T2D, 7.5% of whom had alcohol use disorders (20). The authors demonstrated that T2D patients with alcohol use disorders contributed to 55% of progression to liver-related complications, highlighting the interaction of alcohol with NAFLD (20). The overall prevalence of cirrhosis in T2D patients is not known but cross-sectional data from the US National Health and Nutrition Examination Survey (NHANES), involving liver stiffness measurement using transient elastography (TE) in 825 patients with T2D, found 7.7% had TE measurements equivalent with the presence of cirrhosis (21). These patients were predominantly in the 5th or 6th decade of their life.

The International Diabetes Federation estimates a global diabetes prevalence of 10.5% (equivalent to 537 million adults) in 2021, the majority with T2D (22). Every patient with T2D should have an annual diabetes review, advocated in guidelines from societies such as the UK National Institute for Health and Care Excellence (NICE), the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) (23-25). NICE and ADA have detailed list of complications of T2D that should be monitored for annually (Table 1). These include key indices of health and risk stratification for comorbidities and complications of T2D such as cardiovascular diseases, nephropathy, neuropathy and retinopathy, which are also relevant for the choice of the optimal pharmacological treatment. Annual reviews also offer the opportunity to provide behavioural change advice and support e.g. weight management and signposting to smoking cessation services.

One glaring omission from annual diabetes review recommendations has been until recently the assessment of patients for liver fibrosis (26). In this viewpoint we call for routinely including a liver health check to screen for advanced liver fibrosis as a 10th key care process within the existing framework of an annual diabetes review.

Proposal

We are proposing the inclusion of a “*Liver Health check*” into the existing diabetes annual review (Table 1). The primary aim of such an intervention would be to screen for advanced liver fibrosis, in order to further facilitate behavioural change, specialist input and pharmacological interventions. Currently, detection of liver disease in the community is based on ad-hoc testing by primary care practitioners or endocrinologists in patients suspected of liver disease, typically in response to abnormal liver blood tests or an incidental finding of fatty liver on an abdominal ultrasound performed for another indication such as unspecific abdominal discomfort. This is both inefficient, as it does not systemically assess liver fibrosis in this highly prevalent population, and costly in terms of missed cases, as demonstrated by the success of various community strategies to augment the detection of liver disease (27-29). Cost comparison modelling for detection of NAFLD has repeatedly showed that utilising an algorithm based on non-invasive tests (NITs) for liver fibrosis was superior to standard of care practices (30, 31). Markov modelling of comparative strategies for screening for NAFLD in T2D patients has shown that screening with liver blood tests and TE is the most cost-effective approach (32).

Furthermore, the use of abnormal liver blood tests alone is notoriously unreliable in patients with hepatic steatosis and insufficient to detect advanced liver disease. Liver enzymes show a poor correlation with fibrosis stage and are often normal in cirrhosis (33). For T2D, Kotronen et al. demonstrated that serum alanine aminotransferase did not correspond with the presence of steatosis amongst diabetic patients compared to non-diabetic patients with matched body mass index (BMI) (34). This was despite the T2D group having 80% more steatosis and 16% more visceral adiposity compared to the non-diabetic group (34). A high prevalence of NASH and cirrhosis was recently reported in people with T2D and normal ALT (14, 15).

Patients with T2D have a prevalence of advanced liver fibrosis of more than 10% in most studies (Table 2). A recent French study demonstrated that in a cohort of 330 patients with T2D, NAFLD and abnormal ALT (defined as >30 in males and >20 in females), the prevalence of biopsy-proven advanced fibrosis or cirrhosis was 38% (35). Screening directly for liver fibrosis in one-stop clinical assessments will likely contribute to improved linkage to care.

When screening for advanced fibrosis, we need to acknowledge that we are using non-invasive fibrosis tests validated in patients with chronic liver disease in the secondary care setting and applying them to a T2D population with a lower prevalence of advanced fibrosis. Using such tests liberally introduces spectrum bias and increases the risk of false positive results (36). To mitigate this, the index test must have a high sensitivity and negative predictive value, such as a Fibrosis-4 (FIB-4) cut-off of <1.3 . This has a negative predictive value of $>95\%$ in low prevalence populations (30). This can also be used to rule out advanced fibrosis in patients with NAFLD, ARLD or viral hepatitis and does not require a confirmed diagnosis of liver disease prior to checking. By using FIB-4 in this setting, more than 50% of patients will have a low score and will not require further testing (37).

If a FIB-4 is greater than 1.3, a second test such as Enhanced Liver Fibrosis (ELF) test or TE should then be performed for further risk stratification for advanced fibrosis (Figure 1). A two-step risk stratification process is now supported by EASL (36), the American Association for the study of Liver Disease (AASLD) (38), the American Association of Clinical Endocrinology AACE (26) and the American Gastroenterology Association (39) and has been demonstrated to increase diagnostic accuracy for fibrosis detection in community screening strategies (27). Two-step risk stratification strategies are more cost-effective than the sole use of ELF, FibroScan® or standard of care (31). A strategy using FIB-4 >1.3 followed by TE has a higher positive predictive value for significant fibrosis and leads to lower resource utilization and healthcare costs if applied in those with T2D as opposed to the general population (40). In the T2D population, the Edinburgh Type 2 Diabetes Study showed high negative agreement, i.e. ruling out fibrosis, but poor positive agreement between NITs, highlighting the importance of concordant NITs to rule in fibrosis (41, 42). These studies support the health and economic benefit of a Liver Health Check in people with T2D.

A FIB-4 test is not without limitations. The predictive performance of FIB-4 is suboptimal at the extremes of age, with low sensitivity in those age <35 years, and low specificity in those of age >65 . McPherson et al showed that a higher low-threshold of 2.0 improved specificity in patients greater than 65 years (43). It does however have excellent diagnostic accuracy in ruling out advanced fibrosis, which is its intended use in the proposed algorithm. It is also questionable whether it is valuable to be diagnosing fibrosis stage 2 or 3 in unselected patients over the age of 75 years (44), particularly if these patients have suspected NAFLD. This is in the context that NAFLD fibrosis progression rates are relatively slow. Following a meta-analysis of paired-biopsy studies, Singh et al estimated that in patients with NASH it took seven years to progress between fibrosis stages (45). A pragmatic decision in this context to avoid overburdening primary and secondary care services would be to utilise the Charlson

comorbidity index (46) to exclude from screening anyone with a low 10-year survival probability. Finally, in patients with low FIB-4 and/or TE/ELF, re-testing could potentially happen every 2-3 years rather than annually. As effective pharmacological treatment gets approved, the diagnostic and therapeutic window for such patients may, however, change.

Pros

By embedding a “*Liver Health Check*” in an annual diabetes review (Figure 1), the awareness of liver disease and NAFLD amongst primary care practitioners and other specialists is expected to increase. This is important as NAFLD is an often-neglected component of the metabolic syndrome that also requires assessment and risk stratification, whereas alcohol use in T2D is commonly overlooked (47).

Such an approach would increase the detection of clinically relevant liver disease in a high-risk group for NAFLD and associated advanced fibrosis or cirrhosis. FIB-4 is inexpensive (in the UK, the estimated cost is £0.12) and easily accessible. Incorporating FIB-4 into an annual diabetes review has already been piloted by Mansour et al with the Gateshead Pathway. T2D patients were screened with age-based cut-offs. If the FIB-4 were elevated, patients were referred for a hospital-based TE assessment (48). The authors found almost 20% of T2D screened had an elevated FIB-4, with a fifth of patients referred to hepatology having evidence of cirrhosis on TE, while 50% had stiffness values <8 KPa (48). Furthermore, their TE clinic attendance rate was high at 93%, mainly through pragmatic screening of patients that were deemed appropriate for specialist input (48). This approach of FIB-4 followed by TE to screen for fibrosis is now being advocated in Europe and the US (26, 49).

Ongoing work is important in order to understand the acceptability and feasibility of community-based TE clinics, as this will also determine if TE is an appropriate second step confirmatory test. The Mid-Hampshire pilot, presented in the 2021 UK Lancet Liver Commission, made portable FibroScan® available to general practitioners (GP) in the UK, and reported that the cost of a community-based scan was half of that of an in-hospital scan. Importantly community TE clinics provided high patient and GP satisfaction (50). In the near future, the use of probes that can be connected to a smartphone or laptop and hence will not require a dedicated machine might make point-of-care testing easier.

Whilst lifestyle management of NAFLD and ARLD are not contingent on a diagnosis of liver disease, informing patients they have liver fibrosis can alter their behaviour. A meta-analysis exploring the effectiveness of adding advice based on liver injury biomarkers to patients with alcohol misuse showed that patients receiving advice had substantial reduction in weekly alcohol consumption, improvement in the γ -glutamyl transferase level and reduced mortality

(51). The same group are exploring prospectively if knowledge of liver fibrosis can affect high risk drinking behaviour in the KLIFAD randomised controlled trial (52). Kjægaard et al presented outcomes of lifestyle modification on a prospective cohort of 2,764 individuals screened for liver fibrosis with TE, and reported positive behavioural change in both NAFLD and ARLD (53). Amongst individuals at risk of ARLD, 50% were abstinent or had reduced alcohol intake a week later and this effect was sustained at 6 months (53). A similarly significant response was seen amongst individuals informed about their risk of NAFLD, with 34% of them reporting they consumed less food and/or more healthy food. Patients in diabetes clinics are at risk primarily of NAFLD with or without ARLD, therefore the results of this study is generalizable to this setting. However, outcomes for lifestyle advice provided to people with NAFLD is more contentious. The BALLETS prospective cohort study found that telling patients with NAFL to improve their weight resulted in mainly provoking short-term anxiety (54). Clearly, prospective research is required in order to better quantify the potential behavioural changes following non-invasive fibrosis investigations. Furthermore, the diagnosis of NAFLD with fibrosis has implications on the choice of anti-diabetic treatment as outlined in recent guidelines (26) and will also make patients eligible for future NASH-specific pharmacotherapy when approved.

Ultimately, in a landscape where the index presentation for over 70% of patients with new liver disease is acutely to hospital, with an inpatient mortality as high as 15% (55), early detection of liver disease can provide significant value to patients and health systems. Furthermore, it also allows for the identification of patients with cirrhosis that would benefit from HCC surveillance and portal hypertension screening.

Barriers

To embed such a change in an established annual review process requires engagement from stakeholders, specifically primary care specialists and diabetologists. Despite mounting evidence and support from EASL (49), EASD (56), ADA (57) and the AACE (26) to test T2D patients for liver fibrosis, adoption of this strategy has been suboptimal at the national level. In addition, gastroenterologists and hepatologists should accept that part of early detection of liver disease will involve better engagement and overall coordination with primary care services, endocrinology and cardiology clinics and effective strategies to cope with the large number of referrals that would result if all T2D patients were tested with NITs.

The potential harms of screening, including patient anxiety and/or difficulty in getting medical insurance should also be acknowledged. The anxiety caused by a positive first test can be mitigated provided there is a rapid resolution in terms of a final diagnosis. This will require efficient automated pathways with reflex testing. Information leaflets on non-invasive testing

and liver disease would also be helpful. A true positive diagnosis of advanced fibrosis or cirrhosis would ultimately be beneficial for patients and would outweigh potential harms.

The availability of NITs is also variable, whilst cut-off values for these tests remains unstandardised (58). Individual NITs have well documented weaknesses, however in combination they can provide an accurate estimate of fibrosis in the majority of patients tested. LSM requires training and the readings can be influenced by morbid obesity, with data from a prospective study in NAFLD suggesting that the applicability is 97% (59). There is also a well-documented variation of elastography measurements of more than 20% in up to 50% of subjects that should be taken into account in the interpretation of results (60). The ELF score can be false positive in people with extra-hepatic inflammatory conditions as it is not liver specific or in advanced age. In a general population sample of 1,973 individuals and low prevalence of fibrosis, 12% had a high ELF value and the majority were false positives (61). Therefore, a combination of sequential NITs might be required for a conclusive diagnosis. FIB-4 can be automatically calculated in laboratories similar to estimated glomerular filtration rate and reported with a traffic light system (green/amber/red) to facilitate interpretation and prompt further action from clinicians. Portable TE machines or shear-wave elastography modules in regular ultrasounds can be used in primary care but this will require the purchase and maintenance of relatively expensive equipment and is unlikely to be available in low-income settings. If community-based TEs become widespread, the physical capacity for an additional clinic is another logistical hurdle to consider for primary care practitioners. Alternatively, hospital TE clinic capacity would need to be increased. This would invariably require additional material investment and healthcare budget allocation.

Prevalence estimates for cirrhosis in the general population range between 0.1-1.7% (62). Screening for liver disease in the general population would most likely not meet the World Health Organization's adapted criteria from the original Wilson and Jungner statement (63). However, targeted screening in a high-risk group such as the diabetic population would be an acceptable practice (64). In a previously published pathway of non-invasive testing of unselected patients with NAFLD with a 5% prevalence of advanced fibrosis, 30% of the patients referred had advanced fibrosis or cirrhosis (27) and these data were replicated in a recent study on patients at risk for NAFLD or ARLD (61). Assuming a prevalence of advanced fibrosis in the diabetic population of 10% and therefore a higher pre-test probability than unselected NAFLD, the expectation is that the false positive results will be lower. Fundamentally, we need cost-effectiveness data for screening high risk groups with prospective cohorts such as during an annual diabetes review (64). Such studies would provide data on the combination of risk factors that would make screening cost-effective, optimal age cut-offs and frequency of re-testing. Cost-effectiveness data will also be

influenced from the future availability of approved treatments for fibrotic NASH but also from the effectiveness of lifestyle modifications following non-invasive testing. We also need prospective data to have clarity on which combination of NITs have greatest diagnostic accuracy whilst being most acceptable to patients (42). Currently those data are limited; however, ongoing studies will provide more information in the near future (65). Finally, we need to address the stigma related to the diagnosis of liver disease, which can lead to avoiding or delaying care and worse health outcomes (66).

Conclusion

In summary, patients with T2D are a high-risk group for clinically relevant liver disease, predominantly due to NAFLD. In the context of rising NAFLD-related morbidity and mortality, utilising the existing framework of annual diabetes reviews to screen this high-risk group is pragmatic and valuable. FIB-4 is an inexpensive, effective, widely available NIT that can be used as part of a Liver Health check index screening tool in regular health check-up of patients with T2D to detect advanced fibrosis.

References

1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. *Hepatology*. 2023.
2. Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Gastroenterology & Hepatology*. 2020;5(3):245-66.
3. Flemming JA, Djerboua M, Groome PA, Booth CM, Terrault NA. NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. *Hepatology*. 2021;74(6):3330-44.
4. Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. *The New England journal of medicine*. 2021;385(17):1559-69.
5. Nouredin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhoury N, et al. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. *The American journal of gastroenterology*. 2018;113(11):1649-59.
6. Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, et al. Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. *Lancet*. 2018;391(10125):1097-107.
7. de Graaf EL, Kench J, Dilworth P, Shackel NA, Strasser SI, Joseph D, et al. Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index. *J Gastroenterol Hepatol*. 2012;27(3):540-6.
8. Rungay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. *Journal of hepatology*. 2022;77(6):1598-606.
9. Reig M, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, et al. Should Patients with NAFLD/NASH Be Surveyed for HCC? *Transplantation*. 2019;103(1):39-44.
10. Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. *J Hepatol*. 2019;70(3):531-44.
11. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: a consensus statement. *Nat Rev Gastroenterol Hepatol*. 2022;19(1):60-78.
12. Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? *J Hepatol*. 2022;76(4):771-80.
13. Lazarus JV, Ekstedt M, Marchesini G, Mullen J, Novak K, Pericas JM, et al. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. *Journal of hepatology*. 2020;72(1):14-24.
14. Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. *Journal of hepatology*. 2023;78(3):471-8.
15. Castera L, Laouenan C, Vallet-Pichard A, Vidal-Trécan T, Manchon P, Paradis V, et al. High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold. *Diabetes Care*. 2023;46(7):1354-62.
16. Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. *Lancet Diabetes Endocrinol*. 2021;9(3):165-73.

17. Pearson-Stuttard J, Cheng YJ, Bennett J, Vamos EP, Zhou B, Valabhji J, et al. Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records. *Lancet Diabetes Endocrinol.* 2022;10(1):46-57.
18. Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. *JHEP Rep.* 2019;1(4):312-28.
19. Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. *Diabetes Care.* 2018;41(2):372-82.
20. Mallet V, Parlati L, Martinino A, Scarano Pereira JP, Jimenez CN, Sakka M, et al. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. *J Hepatol.* 2022;76(2):265-74.
21. Ciardullo S, Monti T, Perseghin G. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes. *Diabetes Care.* 2021;44(2):519-25.
22. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract.* 2022;183:109119.
23. American Diabetes Association Professional Practice C. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022. *Diabetes Care.* 2022;45(Suppl 1):S39-S45.
24. NICE. Type 2 diabetes in adults: management. National Institute for Health and Care Excellence 2015;NG28.
25. Chung WK, Erion K, Florez JC, Hattersley AT, Hivert MF, Lee CG, et al. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2020;43(7):1617-35.
26. Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr Pract.* 2022;28(5):528-62.
27. Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. *Journal of hepatology.* 2019;71(2):371-8.
28. Dillon JF, Miller MH, Robinson EM, Hapca A, Rezaeihehemi M, Weatherburn C, et al. Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care. *Journal of hepatology.* 2019;71(4):699-706.
29. Chalmers J, Wilkes E, Harris R, Kent L, Kinra S, Aithal G, et al. Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. *Frontline Gastroenterology.* 2020;11(2):86-92.
30. Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodriguez-Peralvarez M, et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. *Health technology assessment (Winchester, England).* 2015;19(9):1-409, v-vi.
31. Srivastava A, Jong S, Gola A, Gailer R, Morgan S, Sennett K, et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. *BMC gastroenterology.* 2019;19(1):122.
32. Nouredin M, Jones C, Alkhouri N, Gomez EV, Dieterich DT, Rinella ME, et al. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. *Gastroenterology.* 2020;159(5):1985-7 e4.
33. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. *Hepatology.* 2003;37(6):1286-92.

34. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. *Diabetes Care*. 2008;31(1):165-9.
35. Castera L, Vidal-Trecan T, Vallet Pichard A, Gault N, Paradis V, Czernichow S, et al. High rate of biopsy-proven advanced fibrosis among type 2 diabetes patients screened for NAFLD in diabetes units. *Hepatology*. 2021;74:1017A.
36. European Association for the Study of the L, List of panel m, Berzigotti A, Boursier J, Castera L, Cazzagon N, et al. Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update. *J Hepatol*. 2021.
37. Crossan CM, A; Srivastava, A; Thorburn, D; Rosenberg, W; Pinzani, M; Longworth, L; Tsochatzis, E. . Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: diagnostic accuracy and cost analysis. *Liver International*. 2019;In Press.
38. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. 2023.
39. Kanwal F, Shubrook JH, Adams LA, Pfothenauer K, Wai-Sun Wong V, Wright E, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2021;161(5):1657-69.
40. Udompap P, Therneau TM, Canning RE, Benson JT, Allen AM. Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population. *Hepatology*. 2022.
41. Morling JR, Fallowfield JA, Guha IN, Nee LD, Glancy S, Williamson RM, et al. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. *J Hepatol*. 2014;60(2):384-91.
42. Majumdar A, Campos S, Gurusamy K, Pinzani M, Tsochatzis EA. Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study. *Hepatology*. 2020;71(2):627-42.
43. McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. *American Journal of Gastroenterology*. 2017;112(5):740-51.
44. Lin H, Yip TC, Zhang X, Li G, Tse YK, Hui VW, et al. Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease. *Hepatology*. 2023;77(2):573-84.
45. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. *Clin Gastroenterol Hepatol*. 2015;13(4):643-54 e1-9; quiz e39-40.
46. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *Journal of Chronic Diseases*. 1987;40(5):373-83.
47. Staufer K, Huber-Schönauer U, Strebinger G, Pimingstorfer P, Suesse S, Scherzer TM, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. *Journal of hepatology*. 2022;77(4):918-30.
48. Mansour D, Grapes A, Herscovitz M, Cassidy P, Vernazza J, Broad A, et al. Embedding assessment of liver fibrosis into routine diabetic review in primary care. *JHEP Rep*. 2021;3(4):100293.
49. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. *Journal of hepatology*. 2021;75(3):659-89.
50. Harriet Gordon RH, Andrew Baring, Amanda Waite, Claire Jackson, Ben Inglis. PWE-24 Mid Hampshire community pathway for identification of those at risk of significant liver injury VGut. 2021;70.
51. Subhani M, Knight H, Ryder S, Morling JR. Does Advice Based on Biomarkers of Liver Injury or Non-Invasive Tests of Liver Fibrosis Impact High-Risk Drinking Behaviour: A Systematic Review With Meta-analysis. *Alcohol Alcohol*. 2021;56(2):185-200.

52. Subhani M, Jones KA, Sprange K, Rennick-Egglestone S, Knight H, Morling JR, et al. Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD)? protocol for a feasibility randomised controlled trial. *BMJ Open*. 2021;11(11):e054954.
53. Kjærgaard M, Lindvig KP, Hansen JK, Sørensen SL, Johansen S, Thorhauge K, et al. Does screening for liver fibrosis change alcohol consumption, diet, and exercise? A prospective cohort study on the consequences of screening in 2,764 individuals. *Journal of Hepatology*. 2022;77:S35-S6.
54. Zoe T, Jane C, Rebecca H, Joe W, Guha IN, Morling JR. Health related quality of life in individuals at high risk of chronic liver disease: Impact of a community diagnostic pathway. *Public health in practice (Oxford, England)*. 2020;1:100033-.
55. Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, et al. Addressing liver disease in the UK: A blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. *The Lancet*. 2014;384(9958):1953-97.
56. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016;64(6):1388-402.
57. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. *Diabetes Care*. 2023;46(Suppl 1):S49-s67.
58. Lazarus JV, Castera L, Mark HE, Allen AM, Adams LA, Anstee QM, et al. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice. *JHEP Reports*. 2022.
59. Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2019;156(6):1717-30.
60. Nascimbeni F, Lebray P, Fedchuk L, Oliveira CP, Alvares-da-Silva MR, Varault A, et al. Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2015;13(4):763-71.e1-6.
61. Kjaergaard M, Lindvig KP, Thorhauge KH, Andersen P, Hansen JK, Kastrup N, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. *Journal of hepatology*. 2023.
62. Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. *Lancet Gastroenterology & Hepatology*. 2017;2(4):288-97.
63. Wilson JJ, G. Principles and practice of screening for disease. World Health Organization. 1968.
64. Gines P, Castera L, Lammert F, Graupera I, Serra-Burriel M, Allen AM, et al. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. *Hepatology*. 2022;75(1):219-28.
65. Graupera I, Thiele M, Ma AT, Serra-Burriel M, Pich J, Fabrellas N, et al. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries. *BMC Public Health*. 2022;22(1):1385.
66. Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. *Lancet*. 2022;399(10319):61-116.
67. NICE. Supporting the management of type 2 diabetes with pharmacist-led reviews and implementing NICE recommended nine key care processes. National Institute for Health and Care Excellence. 2018.
68. American Diabetes Association Professional Practice C, American Diabetes Association Professional Practice C, Draznin B, Aroda VR, Bakris G, Benson G, et al. 4. Comprehensive Medical

Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022. *Diabetes Care*. 2022;45(Suppl 1):S46-S59.

69. Dai CY, Fang TJ, Hung WW, Tsai HJ, Tsai YC. The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. *Biomedicines*. 2022;10(7).
70. Trifan A, Stratina E, Nastasa R, Rotaru A, Stafie R, Zenovia S, et al. Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter. *Diagnostics (Basel)*. 2022;12(7).
71. Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, et al. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. *Diabetes Care*. 2021;44(2):399-406.
72. Lee CH, Seto WK, Jeong K, Lui DTW, Fong CHY, Wan HY, et al. Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. *Endocrinol Metab (Seoul)*. 2021;36(1):134-45.
73. Gupta A, Anoop S, Ansari IA, Prakash S, Misra A. High prevalence of hepatic steatosis and hepatic fibrosis in patients with type 2 diabetes mellitus. *Clin Nutr ESPEN*. 2021;46:519-26.
74. Lombardi R, Airaghi L, Targher G, Serviddio G, Maffi G, Mantovani A, et al. Liver fibrosis by FibroScan((R)) independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. *Liver Int*. 2020;40(2):347-54.
75. Lai LL, Wan Yusoff WNI, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. *J Gastroenterol Hepatol*. 2019;34(8):1396-403.
76. Zhao H, Song X, Li Z, Wang X. Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus. *Medicine (Baltimore)*. 2018;97(37):e12356.
77. Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. *Gut*. 2016;65(8):1359-68.
78. Harman DJ, Ryder SD, James MW, Wilkes EA, Card TR, Aithal GP, et al. Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography. *Alimentary pharmacology & therapeutics*. 2018;47:504-15.
79. Grgurevic I, Salkic N, Mustapic S, Bokun T, Podrug K, Marusic S, et al. Liver and Nonliver-Related Outcomes at 2 Years Are Not Influenced by the Results of the FIB-4 Test and Liver Elastography in a Real-Life Cohort of Patients with Type 2 Diabetes. *Can J Gastroenterol Hepatol*. 2021;2021:5582813.
80. Ouzan D, Mosnier A, Penaranda G, Daviaud I, Joly H, Muntlak M, et al. Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease. *Eur J Gastroenterol Hepatol*. 2021;33(1S Suppl 1):e986-e91.
81. Giorda CB, Picariello R, Tartaglino B, Nada E, Linzalata C, Romeo F, et al. Hepatic fibrosis of any origin in a large population of type 2 diabetes patients. *Nutr Metab Cardiovasc Dis*. 2021;31(10):2887-94.
82. Lee HW, Lee JS, Kim BK, Park JY, Kim DY, Ahn SH, et al. Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2years. *J Diabetes Complications*. 2021;35(1):107747.
83. Leite NC, Cardoso CRL, Salles GF. Importance of non-invasive liver fibrosis scores for mortality and complications development in individuals with type 2 diabetes. *J Diabetes Complications*. 2021;35(5):107879.

Table 1. Themes for annual assessment in patients with type 2 diabetes (adapted from NICE and ADA). (67, 68).

Ten key care processes to perform during annual diabetes review
1. Glycated haemoglobin (HbA1c) measurement, with a suggested target of 59 mmol/mol
2. Blood pressure (BP) measurement, with a suggested target of 140/80 mm Hg
3. Cholesterol level measurement, with a suggested target for total cholesterol (TC) of 5 mmol/L.
4. Assessment for retinopathy with retinal screening
5. Assessment for neuropathy with foot checks
6. Assessment for nephropathy with urinary albumin testing & serum creatinine testing
7. Atherosclerotic cardiovascular disease risk factors and 10-year risk assessment
8. Weight check and lifestyle management
9. Smoking status check
10. Liver Health Check: Case finding for liver fibrosis with FIB-4 measurement

Non-invasive Test(s)	Setting	T2D N (mean age)	Non-invasive test cut-off	Suspected fibrosis detection*	Definition of advanced fibrosis/cirrhosis	Advanced fibrosis/cirrhosis detection
Transient elastography	Diabetes clinic, secondary care, Taiwan, 2022 (69)	226 (62.1 years)	TE (cut off > 7kPa)	22.1% (n=50/226)	-	-
	Gastroenterology clinic, secondary care, Romania 2022 (70)	424 (53.7 years)	TE (F2 cut off ≥8.2kPa)	31.1% (n=132/424)	TE ≥13.6kPa	10.7% (n=45/424)
	Primary care & Endocrinology clinic, USA, 2021 (71)	561 (60.0 years)	TE (F2 cut off ≥8.2kPa)	14.8% (n=83/561)	TE ≥13.6kPa	3.0% (n=17/361)
	Diabetic Clinic, Hong Kong, 2021 (72)	766 (59.4 years)	TE (F3 cut off ≥9.3kPa)	19.5% (n=149/766)	TE ≥11.5kPa (M probe) TE ≥11kPa (XL probe)	11.7% (n=90/766)
	NHANES cohort study, USA, 2021 (21)	825 (60.6 years)	TE (F2 cut off ≥8.2kPa)	21.7% (n=179/825)	TE ≥13.6kPa	6.3% (n=52/825)
	Diabetes Clinic, secondary care, India, 2021 (73)	250 (51.9 years)	TE (F2 cut off ≥7.1kPa)	62% (n=155/250)	TE ≥13.0kPa	18.4% (n=46/250)
	Diabetes clinics, secondary care, Italy 2019 (74)	394 (68 years)	TE (F2 cut off ≥7.0kPa with M probe; ≥6.2kPa with XL probe)	21% (n=83/394)	-	-
	Diabetes Clinic, secondary care, Malaysia, 2019 (75)	557 (61.4 years)	TE (F3 cut off ≥9.3kPa)	21.0% (117/557)	TE ≥11.5kPa (M probe) TE ≥11kPa (XL probe)	13.5% (n=75/557)
	Secondary care, China, 2018 (76)	629 (47 years)	TE (F2 cut off ≥10.6kPa)	36.7% (n=231/629)	-	-
	Diabetes clinic, secondary care, Hong Kong, 2016 (77)	1918 (60.6 years)	TE (F3 cut off ≥9.6kPa with M probe; ≥9.3kPa with XL probe)	17.4% (n=334/1918)	TE ≥11.5kPa (M probe) TE ≥11kPa (XL probe)	11.7% (n=224/1918)
	Primary care, UK, 2017 (78)	542 (64 years)	TE (F2 cut off ≥8.0kPa)	31.5% (n=171/542)	Hepatologist review (TE +/- histology, endoscopic)	3.7% (n=20/542)


					and sonographic assessment)	
Transient elastography and Magnetic resonance elastography	Primary care & Endocrinology clinic, USA, 2022 (14)	493 (64.4 years)	MRE (F3 cut off ≥ 3.63 kPa) or TE (F3 cut off ≥ 8.8 kPa)	14.0% (n=69/493)	MRE (F4 cut off ≥ 4.67 kPa) or TE (F2 cut off ≥ 15 kPa)	5.9% (n=29/493)
FIB-4 and Transient elastography	Diabetes clinic, secondary care, Croatia, 2021 (79)	454 (64.0 years)	TE (F2 cut off > 7.9 kPa) FIB-4 (≥ 2.67)	TE: 36.1% (n=164/454) FIB-4: 3.1% (n=14/454)	TE ≥ 11.5 kPa	7.3% (n=33/454)
	Primary care, UK, 2021 (48)	466 (63.8 years)	FIB-4 (≥ 1.3 if 35–65 years; ≥ 2.0 if > 65 years) TE (F2 cut off ≥ 8 kPa)	18.2% (n=85/466) had elevated FIB-4 43.1% had elevated TE (n= 25/58)†	TE ≥ 15 kPa	22.4% (n=13/58)
Fibrosis-4 score	Primary care, France, 2021 (80)	214 (62 years)	FIB-4 (≥ 1.3 if < 65 years; ≥ 2.0 if ≥ 65 years)	FIB-4: 15.0% (n=32/214)	-	-
	Diabetes clinics, secondary care, Italy, 2021 (81)	71285 (- †)	FIB-4 ≥ 1.3	66.8% (n=47584/71285)	FIB-4 > 2.67	20.9% (n=14888/71285)
	Diabetes clinics, secondary care, South Korea, 2021 (82)	1292 (60.8 years)	-	-	FIB-4 > 2.67	6.4% (n=83/1292)
	Diabetes clinics, secondary care, Italy, 2020	1429 (- †)	FIB-4 (≥ 1.3 if < 65 years; ≥ 2.0 if ≥ 65 years) -	- 20.7% (n=295/1429)	FIB-4 > 2.67	5.3% (n=76/1429)
Fibrosis-4 score + NAFLD Fibrosis Score	Rio-T2D Cohort Study, Brazil, 2021 (83)	554 (60.3 years)	FIB-4 (≥ 1.3 if < 65 years; ≥ 2.0 if ≥ 65 years) NFS (> 1.455 if < 65 years; ≥ 0.12 if ≥ 65 years)	FIB-4: 13.9% (n=77/554) NFS: 54.2% (n=300/554)	NFS > 0.676	12.8% (n=71/554)
Non-invasive tests & Liver biopsy	QUID-NASH project, France, 2023 (15)	330 (59 years)	Not specified; 1159 T2D patients from 4 diabetes clinics referred to liver clinics with suspected NAFLD	Median FIB-4 1.20 (IQR 0.90-1.69) Median LSM 8.3 (IQR 6.2-11.8)	Histological assessment (NASH CRN)	NASH: 58% ‡ F3: 28% F4: 10%

Table 2. Studies presenting fibrosis prevalence in T2D populations (without previously diagnosed liver disease) using NITs. Only studies with at least 200 participants are reported.

† - Mean age not reported. ‡ - *n* not reported

Abbreviations: CRN: Clinical Research Network; FIB-4: Fibrosis-4 score; NASH: Nonalcoholic steatohepatitis; NFS: NAFLD Fibrosis Score; TE: Transient elastography; T2D: Type 2 diabetes

Figure 1. Suggested pathway for use of non-invasive fibrosis tests incorporated into annual type 2 diabetes checks. Patients with a FIB-4 of ≥ 1.3 , should have further testing with ELF or a Fibroscan, depending on local availability. If the ELF is >9.8 or the LSM is >8 KPa, then these patients should be evaluated in secondary care by a hepatologist. If the FIB4 is <1.3 in the first step of the algorithm or the ELF or LSM are <9.8 or <8 KPa respectively, then the patient does not require hepatological input and should be managed for his/her cardiovascular risk factors.



Footnote: ELF – Enhanced Liver Fibrosis test; FIB-4 – Fibrosis-4 score; LSM – liver stiffness measurement; T2D – type 2 diabetes mellitus